{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:00:21Z","timestamp":1792746021914,"version":"4.5.0"},"reference-count":35,"publisher":"Informa UK Limited","issue":"19-20","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2024,10,17]]},"DOI":"10.1080\/17576180.2024.2411925","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T05:49:13Z","timestamp":1731563353000},"page":"1067-1091","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Harmonization of Vaccine Ligand Binding Assays Validation"],"prefix":"10.1080","volume":"16","author":[{"given":"Francis","family":"Dessy","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Sonderegger","sequence":"additional","affiliation":[{"name":"Takeda, Opfikon, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Wagner","sequence":"additional","affiliation":[{"name":"US FDA, Silver Spring, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Buoninfante","sequence":"additional","affiliation":[{"name":"EU EMA, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenu","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"UK MHRA, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Agnes","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Aksyuk","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Baclin","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bonhomme","sequence":"additional","affiliation":[{"name":"PPD, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Cloney-Clark","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Corsaro","sequence":"additional","affiliation":[{"name":"Ocugen, Malvern, PA, USA (currently at Corsaro Bioanalytical Consulting)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Tavares","family":"Neto","sequence":"additional","affiliation":[{"name":"Brazil ANVISA, Brasilia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Fries","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Gagnon","sequence":"additional","affiliation":[{"name":"IQVIA Laboratories Vaccines, Laval, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Garofolo","sequence":"additional","affiliation":[{"name":"BRI Frontage, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Giardina","sequence":"additional","affiliation":[{"name":"Pfizer, Pearl River, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Green","sequence":"additional","affiliation":[{"name":"PPD, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Guimera","sequence":"additional","affiliation":[{"name":"Janssen, Leiden, South Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Harris","sequence":"additional","affiliation":[{"name":"HilleVax, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Helmy","sequence":"additional","affiliation":[{"name":"Merck, West Point, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Huleatt","sequence":"additional","affiliation":[{"name":"Bill &amp; Melinda Gates Medical Research Institute, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ishii-Watabe","sequence":"additional","affiliation":[{"name":"Japan MHLW, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Jaeger","sequence":"additional","affiliation":[{"name":"IQVIA Laboratories Vaccines, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewal","family":"Jani","sequence":"additional","affiliation":[{"name":"Takeda, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Janssen","sequence":"additional","affiliation":[{"name":"Janssen, Leiden, South Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kierstead","sequence":"additional","affiliation":[{"name":"PPD, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Makar","sequence":"additional","affiliation":[{"name":"Bill &amp; Melinda Gates Foundation, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Marshall","sequence":"additional","affiliation":[{"name":"Moderna, Mystic, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mayer","sequence":"additional","affiliation":[{"name":"Austria AGES \/ EU EMA, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulcyane Neiva","family":"Mendes","sequence":"additional","affiliation":[{"name":"Brazil ANVISA, Brasilia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Murphy","sequence":"additional","affiliation":[{"name":"Sanofi, Swiftwater, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankeetha","family":"Nadarajah","sequence":"additional","affiliation":[{"name":"WRIB, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Nolan","sequence":"additional","affiliation":[{"name":"Merck, West Point, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Plested","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Scully","sequence":"additional","affiliation":[{"name":"Pfizer, Pearl River, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Solstad","sequence":"additional","affiliation":[{"name":"Norway NoMA \/ EU EMA, Oslo, Norway (currently at GE Healthcare)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Stoop","sequence":"additional","affiliation":[{"name":"Janssen, Leiden, South Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Tan","sequence":"additional","affiliation":[{"name":"Pfizer, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Verch","sequence":"additional","affiliation":[{"name":"Merck, West Point, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Wilkins","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arron","family":"Xu","sequence":"additional","affiliation":[{"name":"Inovio Pharmaceuticals, San Diego, CA, USA (currently at Kiniksa)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Moderna, Mystic, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Novavax, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2021-0007"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2019-0271"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2022-0081"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2023-0151"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2023-0135"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17576180.2024.2340961"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2024-0024"},{"key":"e_1_3_7_9_1","volume-title":"Bioanalytical Method Validation Guidance for Industry","author":"US Department of Health and Human Services","year":"2018","unstructured":"US Department of Health and Human Services. Food and Drug Administration (US FDA). Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM). Bioanalytical Method Validation Guidance for Industry 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf"},{"key":"e_1_3_7_10_1","unstructured":"EMA. Guideline on bioanalytical method validation (EMEA\/CHMP\/EWP\/192217\/2009 Rev.1 Corr.) 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf"},{"key":"e_1_3_7_11_1","volume-title":"ICH Harmonised Guideline. Bioanalytical method validation and study sample analysis M10","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human use","year":"2022","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human use. ICH Harmonised Guideline. Bioanalytical method validation and study sample analysis M10. 2022. https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf"},{"key":"e_1_3_7_12_1","volume-title":"Immunogenicity Testing of Therapeutic Protein Products \u2014 Developing and Validating Assays for Anti-Drug Antibody Detection. Guidance for Industry","author":"US Department of Health and Human Services","year":"2019","unstructured":"US Department of Health and Human Services. Food and Drug Administration (US FDA). Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Immunogenicity Testing of Therapeutic Protein Products \u2014 Developing and Validating Assays for Anti-Drug Antibody Detection. Guidance for Industry 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug"},{"key":"e_1_3_7_13_1","unstructured":"EMA. Guideline on immunogenicity assessment of therapeutic proteins (EMEA\/CHMP\/BMWP\/14327\/2006 Rev 1.) 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf"},{"key":"e_1_3_7_14_1","volume-title":"Points to Consider Document: Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices","author":"Biomarker Assay Collaborative Evidentiary Considerations Writing Group, Critical Path Institute (C-Path)","year":"2019","unstructured":"Biomarker Assay Collaborative Evidentiary Considerations Writing Group, Critical Path Institute (C-Path). Points to Consider Document: Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices. 2019. https:\/\/c-path.org\/wp-content\/uploads\/2019\/06\/evidconsid-whitepaper-analyticalsectionv2019.pdf"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2018-0287"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.12.197"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2021-0173"},{"key":"e_1_3_7_18_1","volume-title":"The Biomarkers, EndpointS, and other Tools (BEST) Resource","author":"FDA-NIH Biomarker Working Group","year":"2016","unstructured":"FDA-NIH Biomarker Working Group. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US). The Biomarkers, EndpointS, and other Tools (BEST) Resource. 2016. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/"},{"key":"e_1_3_7_19_1","volume-title":"PDUFA VI: Fiscal Years 2018 \u2013 2022","author":"US FDA","unstructured":"US FDA. PDUFA VI: Fiscal Years 2018 \u2013 2022. https:\/\/www.fda.gov\/industry\/prescription-drug-user-fee-amendments\/pdufa-vi-fiscal-years-2018-2022"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2017-4975"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2022-0080"},{"key":"e_1_3_7_22_1","volume-title":"Guidance Document. Analytical Procedures and Methods Validation for Drugs and Biologics","author":"US FDA","year":"2015","unstructured":"US FDA. Guidance Document. Analytical Procedures and Methods Validation for Drugs and Biologics 2015. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/analytical-procedures-and-methods-validation-drugs-and-biologics"},{"key":"e_1_3_7_23_1","volume-title":"Guidance Document. Q14 Analytical Procedure Development","author":"US FDA","year":"2024","unstructured":"US FDA. Guidance Document. Q14 Analytical Procedure Development 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q14-analytical-procedure-development"},{"key":"e_1_3_7_24_1","volume-title":"WHO manual for the preparation of reference materials for use as secondary standards in antibody testing","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO manual for the preparation of reference materials for use as secondary standards in antibody testing 2022. https:\/\/www.who.int\/publications\/m\/item\/who-manual-for-reference-material-for-antibody-testing"},{"key":"e_1_3_7_25_1","volume-title":"Guideline on clinical evaluation of vaccines (EMEA\/CHMP\/VWP\/164653\/05 Rev. 1.)","author":"EMA","year":"2023","unstructured":"EMA. Guideline on clinical evaluation of vaccines (EMEA\/CHMP\/VWP\/164653\/05 Rev. 1.) 2023. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-evaluation-vaccines-revision-1_en.pdf"},{"key":"e_1_3_7_26_1","volume-title":"ICH Harmonized Tripartite Guideline. Validation Of Analytical Procedures: Text And Methodology Q2(R1)","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human use","year":"2005","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human use. ICH Harmonized Tripartite Guideline. Validation Of Analytical Procedures: Text And Methodology Q2(R1) 2005. https:\/\/database.ich.org\/sites\/default\/files\/Q2%28R1%29%20Guideline.pdf"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.2307\/2988267"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.32.10.2441-2447"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.5731\/pdajpst.2012.00867"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2019.1572615"},{"key":"e_1_3_7_31_1","unstructured":"United States Pharmacopeia. General Chapter \u30081032\u3009 Design and Development of Biological Assays. USP-NF. Rockville MD: United States Pharmacopeia. 2023. https:\/\/doi.usp.org\/USPNF\/USPNF_M1354_01_01.html"},{"key":"e_1_3_7_32_1","unstructured":"United States Pharmacopeia. General Chapter \u30081034\u3009 Analysis of Biological Assays. USP-NF. Rockville MD: United States Pharmacopeia. 2023. https:\/\/doi.usp.org\/USPNF\/USPNF_M5677_02_01.html"},{"key":"e_1_3_7_33_1","unstructured":"European Pharmacopoeia (Ph. Eur.; 2020) 5.3. Statistical analysis of results of biological assays and tests. 01\/2020:50300 European Directorate for the Quality of Medicines & HealthCare."},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.97"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.96"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.01.005"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17576180.2024.2411925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:02:58Z","timestamp":1732089778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17576180.2024.2411925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":35,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2024,10,17]]}},"alternative-id":["10.1080\/17576180.2024.2411925"],"URL":"https:\/\/doi.org\/10.1080\/17576180.2024.2411925","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"value":"1757-6180","type":"print"},{"value":"1757-6199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}